Education
About Us
Working with TipRanks
Follow Us
Pharmaxis Ltd (AU:SNT)
ASX:SNT
SNT Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.10
Previous CloseN/A
Volume5.35M
Average Volume (3M)3.04M
Market Cap
AU$123.44M
Enterprise ValueAU$23.38M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)9.25M
Price to Earnings (P/E)―
Beta2.30
Next Earnings
Aug 27, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding1,624,178,100
10 Day Avg. Volume2,835,181
30 Day Avg. Volume3,044,256
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)13.13
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.25Price Target Upside212.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Pharmaxis Ltd News
PremiumCompany Announcements
Pharmaxis Ltd Announces Substantial Shareholding Disclosure
PremiumCompany Announcements
Syntara Limited Announces Cessation of Performance Rights
PremiumCompany Announcements
Syntara Limited Announces Quotation of New Securities on ASX
PremiumCompany Announcements
Syntara Limited Hosts Webinar on Skin Scarring Program Developments
PremiumCompany Announcements
Syntara Limited to Present at NWR Virtual Healthcare ConferencePremiumCompany Announcements
Syntara Limited Announces Director’s Interest ChangePremiumCompany Announcements
Syntara Limited Reports Significant Revenue Growth and Reduced Losses
PremiumCompany Announcements
Syntara Limited Raises A$15 Million Through New Share Issuance---
Options Prices
Currently, No data available
---
Ownership Overview
3.96% Insiders
―
Mutual Funds
― Other Institutional Investors
96.04% Public Companies and
Individual Investors
SNT FAQ
What was Pharmaxis Ltd’s price range in the past 12 months?
Pharmaxis Ltd lowest share price was AU$0.01 and its highest was AU$0.10 in the past 12 months.
What is Pharmaxis Ltd’s market cap?
Pharmaxis Ltd’s market cap is AU$123.44M.
When is Pharmaxis Ltd’s upcoming earnings report date?
Pharmaxis Ltd’s upcoming earnings report date is Aug 27, 2025 which is in 149 days.
How were Pharmaxis Ltd’s earnings last quarter?
Pharmaxis Ltd released its earnings results on Feb 26, 2025. The company reported -AU$0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.004.
Is Pharmaxis Ltd overvalued?
According to Wall Street analysts Pharmaxis Ltd’s price is currently Undervalued.
Does Pharmaxis Ltd pay dividends?
Pharmaxis Ltd does not currently pay dividends.
What is Pharmaxis Ltd’s EPS estimate?
Pharmaxis Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pharmaxis Ltd have?
Pharmaxis Ltd has 1,624,178,100 shares outstanding.
What happened to Pharmaxis Ltd’s price movement after its last earnings report?
Pharmaxis Ltd reported an EPS of -AU$0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Pharmaxis Ltd?
Currently, no hedge funds are holding shares in AU:SNT
---
Pharmaxis Ltd Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.25 (212.50% Upside)
AU$0.25 (212.50% Upside)
Blogger Sentiment
Bullish
AU:SNT Sentiment 97%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth AU$585.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
261.90%
12-Months-Change
Fundamentals
Return on Equity
-89.17%
Trailing 12-Months
Asset Growth
55.91%
Trailing 12-Months
Company Description
Pharmaxis Ltd
Pharmaxis Ltd is an Australia based pharmaceutical research company engaged in the research, development, and commercialization of human healthcare products for the treatment and management of fibrotic and inflammatory diseases. The firm's research efforts are focused on discovering drugs to treat inflammatory and fibrotic diseases such as NASH, pulmonary fibrosis, kidney and liver fibrosis and cancer from its amine oxidase inhibitor chemistry platform. Its product pipeline also includes Orbital and ASM8. The operating segments are Mannitol respiratory business and New Drug Development. It generates maximum revenue from Mannitol respiratory business segment.
---
SNT Stock 12 Month Forecast
Average Price Target
AU$0.25
▲(212.50% Upside)
Technical Analysis
Biotron Limited
―
Polynovo Limited
―
Opthea Limited
―
Cynata Therapeutics Limited
―
Immutep Ltd
―
Best Analysts Covering SNT
1 Year
1 Year Success Rate
0/1 ratings generated profit
1 Year Average Return
-5.00%
reiterated a buy rating 19 days ago
Copying Madeleine Williams's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -5.00% per trade.
---